HARTON H LYNN
Known title: President & CEOCIK: 0001257941
Associated companies
Transaction History
| UCB | ▼ Sell | Open Market | 25,000 | $866K | 2/18/2026 | View on chart |
| UCB | ▲ Buy | Grant | 24,542 | $0 | 2/15/2026 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 11,622 | $402K | 2/15/2026 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 9,755 | $337K | 2/15/2026 | View on chart |
| UCB | ▲ Buy | Grant | 33,584 | $0 | 2/12/2026 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 1,090 | $34K | 8/15/2025 | View on chart |
| UCB | ▼ Sell | Open Market | 3,321 | $111K | 2/19/2025 | View on chart |
| UCB | ▲ Buy | Grant | 19,610 | $0 | 2/15/2025 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 509 | $17K | 2/15/2025 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 5,921 | $198K | 2/15/2025 | View on chart |
| UCB | ▼ Sell | Open Market | 30,721 | $1.0M | 2/10/2025 | View on chart |
| UCB | ▼ Sell | Open Market | 958 | $33K | 2/10/2025 | View on chart |
| UCB | ▲ Buy | Grant | 33,215 | $0 | 2/10/2025 | View on chart |
| UCB | ▼ Sell | Gift | 611 | $0 | 12/10/2024 | View on chart |
| UCB | ▼ Sell | Gift | 611 | $0 | 12/10/2024 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 560 | $18K | 11/15/2024 | View on chart |
| UCB | ▼ Sell | Gift | 2,866 | $0 | 10/29/2024 | View on chart |
| UCB | ▼ Sell | Gift | 2,866 | $0 | 10/29/2024 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 2,621 | $75K | 8/15/2024 | View on chart |
| UCB | ▼ Sell | Gift | 8,329 | $0 | 3/13/2024 | View on chart |
| UCB | ▼ Sell | Gift | 8,329 | $0 | 3/13/2024 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 2,254 | $62K | 2/15/2024 | View on chart |
| UCB | ▲ Buy | Grant | 11,227 | $0 | 2/15/2024 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 5,364 | $148K | 2/15/2024 | View on chart |
| UCB | ▲ Buy | Grant | 30,305 | $0 | 1/4/2024 | View on chart |
| UCB | ▼ Sell | Gift | 686 | $0 | 11/29/2023 | View on chart |
| UCB | ▼ Sell | Gift | 686 | $0 | 11/29/2023 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 485 | $12K | 11/15/2023 | View on chart |
| UCB | ▼ Sell | Gift | 4,467 | $0 | 10/31/2023 | View on chart |
| UCB | ▼ Sell | Gift | 4,467 | $0 | 10/31/2023 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 3,151 | $88K | 8/15/2023 | View on chart |
| UCB | ▲ Buy | Grant | 26,573 | $0 | 2/15/2023 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 10,990 | $367K | 2/15/2023 | View on chart |
| UCB | ▲ Buy | Grant | 18,879 | $0 | 1/5/2023 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 1,429 | $54K | 11/15/2022 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 2,975 | $107K | 8/15/2022 | View on chart |
| UCB | ▼ Sell | Open Market | 5,000 | $176K | 4/1/2022 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 1,251 | $46K | 2/15/2022 | View on chart |
| UCB | ▲ Buy | Grant | 29,044 | $1.1M | 2/15/2022 | View on chart |
| UCB | ▼ Sell | Open Market | 10,000 | $363K | 1/3/2022 | View on chart |
| UCB | ▼ Sell | Tax Withholding | 1,326 | $48K | 11/15/2021 | View on chart |
| UCB | ▼ Sell | Open Market | 10,000 | $330K | 10/1/2021 | View on chart |
| UCB | ▲ Buy | Grant | 9,125 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
UCB Announces Georgia Biologics Campus and Strong Q3 Activity
United Community Banks has dedicated a site in Georgia for a new U.S. biologics manufacturing campus, expanding its presence in the biotech sector. A recent review notes a busy third quarter that could set the bank up for better financial results. These developments come as the stock trades near its 52‑week high and shows modest momentum on technical indicators.
UCB Announces Georgia Biologics Campus and Strong Q3 Activity. United Community Banks has dedicated a site in Georgia for a new U.S. biologics manufacturing campus, expanding its presence in the biotech sector. A recent review notes a busy third quarter that could set the bank up for better financial results. These developments come as the stock trades near its 52‑week high and shows modest momentum on technical indicators.